due
properti
applic
benzofus
azol
class
heterocycl
compound
great
interest
pharmaceut
chemistri
area
benzimidazol
deriv
studi
decad
drug
heterocycl
moieti
main
element
wide
use
clinic
instanc
anthelmint
human
benzocondens
azol
contain
three
heteroatom
bezoxadiazol
benzothiazol
benzotriazol
extens
studi
broad
rang
biolog
activ
howev
review
focal
singl
nucleu
inde
aim
paper
provid
overview
benzotriazol
base
system
relev
medicin
chemistri
triazol
bt
fig
consid
privileg
structur
sever
pharmacolog
activ
use
scaffold
design
new
pharmacolog
activ
compound
bt
undergo
rapid
develop
synthesi
heterocycl
pure
chemic
point
view
benzotriazol
structur
prove
extrem
versatil
applic
instanc
current
use
synthet
auxiliari
good
leav
group
reaction
varieti
carbonyl
group
particular
interest
use
acylbenzotriazol
methodolog
develop
katrizski
cowork
nacylbenzotriazol
easytohandl
acyl
agent
advantag
n
cand
sacyl
new
peptidomimet
macrocycl
fig
obtain
dicarboxyl
benzotriazol
use
methodolog
benzotriazol
also
act
electrondonor
precursor
radic
carbanion
easili
insert
chemic
structur
seri
reaction
condens
addit
reaction
benzotriazolylalkyl
author
also
report
synthesi
stabl
nitrenium
ion
use
bt
synthon
polymersupport
benzotriazol
also
use
catalyst
gener
tetrahydroquinolin
librari
howev
main
interest
bt
focus
pharmaceut
field
suitabl
substitut
benzotriazol
deriv
boast
differ
biolog
properti
includ
plantgrowth
regul
choleret
antibacteri
antiprotozo
antivir
antiprolif
activ
antimicrobi
activ
benzotriazol
deriv
extens
investig
sinc
late
togeth
azol
ring
becom
one
activ
highlight
recent
year
first
part
twentieth
centuri
discoveri
develop
antibacteri
drug
major
scientif
achiev
despit
invest
antimicrobi
drugdiscoveri
new
drug
class
found
past
year
addit
difficulti
treat
infect
due
antibiot
resist
increas
highlight
urgenc
develop
new
drug
decad
sparator
cowork
studi
character
variou
nitrogen
ring
report
bt
part
larger
heterocycl
system
biolog
activ
especi
antibacteri
sanna
research
group
also
report
relev
benzotriazol
moieti
triazolo
quinolinon
carboxyl
acid
fig
close
relat
oxolin
acid
acid
show
encourag
vitro
antimicrobi
activ
escherichia
coli
minimum
inhibitori
concentr
mic
valu
includ
mgml
moreov
demonstr
annul
differ
posit
triazol
ring
triazolo
h
quinolinon
carboxyl
acid
induc
partial
total
antimicrobi
activ
loss
deriv
acet
describ
alomran
cowork
synthes
varieti
compound
incorpor
bt
thiophen
pyridin
thiadiazol
pyrazol
moieti
fig
test
compound
screen
antimicrobi
activ
result
bactericid
potenti
antibacteri
activ
also
report
substitut
olefin
fatti
acid
fig
purohit
srivastava
synthes
seri
chlorosubstitut
phenoxyacetyl
benzotriazol
compound
screen
antiinflammatori
analges
antibacteri
antifung
properti
show
mild
moder
antibacteri
antifung
activ
notabl
compound
emerg
analges
effect
also
demonstr
even
simpl
benzotriazol
nucleu
possess
antibacteri
activ
similar
antimicrobi
profil
report
seri
heterocyclyl
ethanon
fig
e
phenyldiazenyl
phenyl
methanon
deriv
prepar
jamkhandi
cowork
diazonium
coupl
reaction
compound
show
good
moder
antibacteri
antifung
activ
interest
zone
inhibit
diameth
note
compound
comparison
standard
drug
result
also
report
amino
acet
acid
deriv
nphenylacetamid
deriv
display
less
antibacteri
potenc
structur
depict
fig
vitro
antibacteri
activ
benzimidazol
fig
also
report
ochal
group
compound
test
seri
refer
includ
gramposit
gramneg
bacteria
clinic
strain
includ
methicillinresist
mrsa
methicillinsensit
mssa
staphylococcu
aureu
strain
plu
methicillinresist
staphylococcu
epidermidi
show
signific
antibacteri
activ
wherea
trifluoromethylsubstitu
benzimidazol
deriv
emerg
potenc
inde
abl
inhibit
staphylococci
strain
mrsa
mic
valu
mgml
compar
nitrofurantoin
strain
benzotriazol
also
use
modul
biolog
activ
heterocycl
ring
acridin
b
report
singh
et
al
levofloxacin
deriv
link
carboxyl
moieti
fig
last
case
modif
led
similar
antimicrobi
activ
levofloxacin
gramposit
gramneg
bacteria
da
et
al
synthes
evalu
antimicrobi
agent
pool
novel
oxazolidinon
deriv
fig
benzotriazol
relev
confirm
replac
benzimidazol
benzothiazol
benzoxazol
modif
provid
less
activ
inact
compound
effect
posit
geometr
isomer
triazol
moieti
demonstr
linearli
attach
deriv
show
higher
effici
compar
angular
one
vitro
regard
angular
deriv
eisom
found
potent
zisom
final
thioacetamid
analogu
repres
lead
compound
endow
similar
activ
linezolid
vitro
besid
seri
novel
oxazolidinon
deriv
hold
un
substitutedbenzotriazol
moieti
evalu
panel
suscept
resist
gramposit
gramneg
bacteria
resist
methicillin
vancomycin
introduct
benzotriazol
gener
seri
oxazolidinon
fig
vitro
equipot
much
effici
linezolid
suscept
resist
gramposit
strain
particularli
introduct
ecoom
group
benzotriazol
fifth
posit
led
compound
exhibit
excel
antibacteri
profil
mic
valu
mgml
asati
group
link
benzotriazol
nucleu
deriv
obtain
benzotriazoloacetamidyl
deriv
screen
bacillu
subtili
salmonella
typhimurium
escherichia
coli
bacillu
anthraci
ppm
like
compound
fig
result
equipot
streptomycin
swami
et
al
prepar
seri
nalkyl
benzotriazol
deriv
microwaveassist
synthesi
report
fig
antibacteri
activ
compound
test
bacteri
strain
like
bacillu
subtili
escherichia
coli
pseudomona
fluorescen
xanthomona
campestri
e
xanthomona
oryza
result
highlight
methyl
methyl
triazol
act
potent
antimicrobi
agent
behavior
probabl
due
presenc
bulki
hydrophob
group
cyanobiphenyl
benzodioxol
contrari
smaller
molecul
bear
group
result
equipot
refer
drug
streptomycin
final
even
deriv
demonstr
activ
drugresist
bacteri
strain
compound
lack
select
activ
gramposit
gramneg
bacteria
differ
fungal
strain
differ
author
report
imidazol
triazol
ring
isoster
analog
synthet
relev
associ
varieti
biolog
pharmacolog
activ
similarli
n
substitut
ch
transform
benzimidazol
benzotriazol
deriv
consid
exampl
classic
isoster
replac
lead
idea
ramachandran
colleagu
synthes
seri
new
imidazolebenzotriazol
substitut
deriv
fig
evalu
antibacteri
antifung
activ
pathogen
microbi
strain
studi
highlight
introduct
bulki
substitu
isopropyl
group
piperidin
cycl
posit
increas
antibacteri
activ
bacillu
subtili
imidazol
benzotriazol
deriv
mic
mgml
respect
comparison
refer
drug
streptomycin
similar
behavior
observ
antifung
evalu
good
growth
inhibit
escherichia
coli
report
compound
bear
methyl
group
piperidin
ring
imidazol
deriv
mic
mgml
among
benzotriazol
deriv
best
inhibit
activ
mic
chemic
structur
hit
compound
asati
work
fig
microwaveassist
synthesi
nsubstitut
benzotriazol
deriv
e
coli
mgml
mgml
regist
compound
contain
pfluorophenyl
substitu
piperidin
ring
compound
show
none
moder
growth
inhibit
activ
differ
fungal
strain
except
compound
aspergillu
niger
mg
ml
candida
neoforman
mgml
candida
albican
mgml
rhizopu
speci
mgml
final
suma
research
group
investig
antimicrobi
proprieti
seri
un
substitutedbenzotriazol
link
substitut
moieti
synthes
compound
character
biolog
evalu
cup
plate
diffus
method
examin
deriv
fig
compound
found
compar
ciprofloxacin
staphylococcu
aureu
limit
activ
report
candida
albican
unfortun
sar
analysi
report
solid
complex
ligand
contain
benzotriazol
thioamid
moieti
transit
metal
ion
investig
antimicrobi
agent
new
cu
ni
complex
thioamid
fig
synthes
biolog
activ
evalu
staphylococcu
aureu
salmonella
strain
author
demonstr
ligand
act
bident
ligand
give
distort
tetragon
structur
case
cu
complex
squar
planar
structur
case
ni
differ
justifi
diverg
antimicrobi
behavior
deriv
even
neutral
complex
obtain
case
l
cu
complex
activ
aureu
salmonella
strain
final
littl
known
antiprotozo
activ
benzotriazol
deriv
simpli
substitut
bt
gener
fig
compound
endow
micromolar
activ
entamoeba
histolytica
biolog
behavior
demonstr
scaffold
indazol
nucleu
activ
metronidazol
drug
commonli
use
treatment
anaerob
protozoan
parasit
infect
pagliero
work
demonstr
compound
possess
heterocycl
nucleu
link
benzenesulfonyl
moieti
show
protozoan
antiparasit
properti
basi
fragmentbas
drug
design
strategi
becerra
group
design
prepar
librari
deriv
bt
follow
procedur
report
katrinski
compound
prepar
sulfonyl
group
determin
biolog
vitro
activ
nbenzenesulfonylbenzotriazol
fig
protozoan
parasit
trypanosoma
cruzi
differ
concentr
nbenzenesulfonylbenzotriazolewer
test
epimastigot
trypomastigot
form
demonstr
deriv
vitro
growth
inhibitori
dosedepend
activ
epimastigot
particularli
incub
h
parasit
number
epimastigot
form
decreas
mgml
mgml
condit
bt
use
refer
compound
show
antitrypanosom
activ
compound
fig
imidazolebenzotriazol
substitut
deriv
trypanosoma
cruzi
inhibitor
appear
even
effect
trypomastigot
infect
form
parasit
inde
earlier
time
point
concentr
mgml
compound
induc
trypomastigot
dead
higher
epimastigot
form
contrari
bt
less
effect
caus
dead
parasit
concentr
basi
structur
tbbt
highli
select
inhibitor
protein
kinas
bromo
chloroand
methylanalogu
benzotriazol
nalkyl
deriv
fig
synthes
evalu
vitro
antiprotozo
activ
acanthamoeba
castellanii
trophozoit
cyst
protozoa
well
sever
speci
freeliv
amoeba
belong
genu
acanthamoeba
repres
seriou
risk
human
health
mani
synthes
compound
show
antiprotozo
activ
compar
current
use
drug
chlorohexidin
deriv
show
even
higher
activ
especi
toward
acanthamoeba
cyst
previous
report
sever
author
disclos
biolog
evalu
imidazol
deriv
benzotriazol
analogu
antibacteri
antimycot
agent
unfortun
case
select
action
demonstr
howev
structur
model
bestknown
antifung
drug
fluconazol
offer
interest
start
point
drug
design
studi
inde
triazol
system
replac
benzotriazol
ring
order
evalu
effect
bioisoster
replac
biolog
behavior
concern
mechan
action
known
antimycot
drug
fluconazol
itraconazol
voriconazol
ravuconazol
posaconazol
exert
pharmacolog
action
inhibit
fungal
ademethylas
cytochrom
known
essenti
enzym
biosynthesi
sterol
particular
remov
amethyl
group
lanosterol
use
oxygen
nadph
oxid
transform
ergosterol
essenti
compon
fungal
cell
membran
drug
act
displac
lanosterol
bind
site
caus
block
biosynthesi
ergosterol
accumul
amethylsterol
fluconazol
analogu
crucial
interact
enzymat
activ
site
favor
compon
basic
nitrogen
atom
posit
triazol
moieti
form
bond
acid
iron
heme
prosthet
group
posit
normal
occupi
oxygen
presenc
aromat
ring
molecular
behavior
almost
nonpolar
describ
fig
fluconazol
effect
candidiasi
oral
parenter
administr
ineffect
aspergillosi
besid
observ
increas
incid
infect
caus
candida
albican
candida
glabrata
candida
krusei
resist
drug
evid
greatli
stimul
pharmaceut
research
antimycot
field
lead
synthesi
new
deriv
benzotriazol
group
central
structur
compound
comparison
imidazol
antifung
drug
seem
possess
broader
antifung
spectrum
pair
lower
toxic
perspect
patel
research
group
elid
ring
fluconazol
replac
un
substitut
benzotriazol
lead
compound
eh
fig
particularli
compound
exhibit
potent
antifung
activ
mic
valu
candida
albican
rang
mgml
mgml
moreov
introduct
benzotriazol
ring
small
hydrophob
group
ecl
ech
diech
led
compound
success
candida
aspergillu
spp
mgml
mic
valu
aspergillu
niger
replac
benzotriazol
ring
triazolopyridin
gener
polar
less
potent
analogu
final
introduct
electronwithdraw
group
eno
ecl
ef
posit
benzotriazol
moieti
increas
antimycot
activ
contrari
substitut
posit
led
compound
definit
less
potent
xpglide
dock
method
analysi
demonstr
relev
hydrophob
substitu
molecular
interact
mycobacterium
tuberculosi
select
model
absenc
crystal
structur
fungal
particularli
enantiom
lower
glide
score
express
kcalmol
report
inde
show
antimycot
activ
higher
respect
r
enantiom
furthermor
evalu
interact
differ
bind
site
aminoacid
sequenc
mycobacterium
tuberculosi
aspergillu
niger
compar
obtain
result
show
antifung
potenc
differ
among
benzotriazol
regioisom
coupl
differ
mainli
due
triazol
heterocycl
placement
activ
site
also
rezaei
colleagu
synthes
assort
triazol
deriv
includ
benzotriazol
inhibitor
chemic
structur
benzotriazol
deriv
b
display
fig
synthes
compound
molecular
dock
simul
activ
site
perform
collect
data
result
compar
obtain
use
fluconazol
particular
lower
final
dock
energi
fde
valu
index
better
drugetarget
interact
obtain
triazol
deriv
howev
correl
antifung
activ
fde
analys
underlin
relationship
antimicrobi
potenc
molecular
penetr
fungi
cell
consequ
presenc
bulki
substitu
och
believ
respons
activ
decreas
follow
research
team
head
rezaei
continu
investig
inhibitor
synthes
new
imidazol
benzimidazol
benzotriazol
deriv
fig
throughout
drugdesign
studi
appli
autodock
best
silico
promis
deriv
synthes
antimycot
activ
compar
fluconazol
itraconazol
use
refer
drug
unfortun
benzotriazol
deriv
show
antifung
activ
candida
speci
except
compound
endow
activ
dermatophyt
microsporum
cani
imidazol
deriv
appear
activ
compound
microbi
speci
taken
account
behavior
probabl
due
presenc
fivememb
nitrogen
heterocycl
ring
lower
size
allow
best
access
fungal
cell
relat
azol
antifung
model
new
compound
produc
gaikwad
colleagu
wherein
benzotriazol
core
modifi
alkyl
complic
side
chain
bear
substitut
thiazol
ring
shown
fig
test
wide
number
microorgan
gramposit
gramneg
fungi
case
best
activ
observ
deriv
bear
electron
withdraw
substitu
f
cl
br
side
benzen
phenyl
group
precis
deriv
abl
equal
inhibit
growth
gramposit
gramneg
bacteria
well
candida
albican
aspergillu
niger
growth
modif
side
chain
bt
led
saini
group
develop
new
substitut
deriv
depict
fig
compound
demonstr
possess
good
antifung
activ
chloro
substitut
deriv
activ
unsubstitut
alkyl
substitut
analogu
numer
schiff
base
fig
investig
prasad
et
al
deriv
screen
antifung
activ
use
cup
plate
agar
diffus
method
candida
albican
compound
potent
antifung
effect
moreov
compound
bear
simultan
benzotriazol
thiadiazol
azetidon
moieti
report
shukla
srivastava
antifung
antibacteri
activ
similar
compound
precursor
extens
examin
srivastana
colleagu
compound
depict
fig
investig
antimicrobi
behavior
also
anticonvuls
activ
compound
stood
abl
protect
induc
seizur
way
refer
drug
phenobarbiton
antifung
activ
revel
even
complex
methyl
differ
transit
metal
form
complex
compound
depict
fig
author
demonstr
simpl
ligand
less
toxic
variou
type
fungi
chelat
particularli
cu
chelat
result
one
effect
deriv
worm
infect
common
infect
worldwid
affect
poorest
depriv
commun
recogn
caus
chronic
illhealth
amongst
peopl
live
tropic
subtrop
area
actual
benzimidazol
nucleu
core
anthelmint
broadest
known
spectrum
activ
moreov
similar
activ
report
also
benzotriazol
deriv
benzotriazol
substitu
fig
connect
seri
synthes
sudhir
et
colleagu
ultrason
solvent
free
condit
compound
test
activ
adult
earthworm
pheretima
posthuma
use
mebendazol
albendazol
refer
drug
although
none
test
compound
effect
refer
drug
deriv
f
j
n
show
dosedepend
anthelmint
activ
behavior
attribut
pnitrophenyl
substitu
attach
azo
group
benzotriazol
moieti
moreov
addit
pnitrophenyl
group
provid
best
result
contrari
methyl
design
activ
necatur
americanu
infect
result
total
inact
newborn
hamster
final
alkoxyaryloxi
arylaminomethylen
benzotriazol
describ
good
anthelmint
agent
pheretima
posthuma
anthelmint
activ
deriv
compar
refer
drug
albendazol
moreov
alkoxyaryloxymethylen
benzotriazol
result
potent
alkylaryl
aminomethylen
analogu
despit
percept
nowaday
tuberculosi
tb
still
one
common
infecti
diseas
estim
much
onethird
world
popul
billion
peopl
infect
mycobacterium
tuberculosi
tb
annual
nine
million
new
tb
case
occur
two
million
peopl
die
diseas
even
frighten
rapid
emerg
spread
multidrugresist
mdr
extensivelydrugresist
xdr
tb
strain
region
world
along
deadli
synergi
human
immunodefici
viru
hiv
tb
worldwid
tb
lead
caus
death
among
hivposit
peopl
treatment
activ
tuberculosi
requir
combin
sever
drug
isoniazid
pyrazinamid
ethambutol
rifampicin
streptomycin
use
differ
combin
firstlin
therapi
contrari
quinolon
classifi
secondlin
drug
even
use
recommend
manag
mdrtb
howev
due
outcom
mdr
xdrtb
strain
worldwid
urgent
need
new
drug
act
novel
mechan
action
mention
moreov
new
drug
could
use
develop
regimen
shorter
standard
treatment
regimen
sever
group
focus
attent
research
effort
field
larg
amount
molecul
test
purpos
sinc
carta
cowork
focus
attent
bioisoster
modif
quinolon
result
variou
benzotriazol
deriv
synthes
first
seri
yl
acrylonitril
prepar
aim
identifi
best
substitu
aryl
moieti
group
hold
variou
electronacceptor
donor
properti
lipophilicehydrophil
balanc
opportun
select
synthesi
perform
knoevenagel
condens
case
result
format
eisom
case
mixtur
ezisom
observ
preliminari
studi
benzotriazol
deriv
result
activ
isom
unsubstitut
phenyl
moieti
outcom
best
option
exhibit
highest
antimycobacteri
activ
vitro
also
mycobacterium
avium
except
repres
deriv
although
activ
result
lower
one
depict
fig
aim
improv
antimycobacteri
activ
modif
perform
introduct
phenyl
ring
two
electronreleas
group
replac
phenyl
ring
cyclohexyl
larger
aromat
ring
unfortun
produc
yl
propeno
acid
show
strong
reduct
loss
activ
spite
increas
lipophil
charact
indic
steric
hindranc
well
natur
substitu
may
play
relev
role
determin
abil
inhibit
tb
prolifer
final
order
extend
sar
studi
variou
substitu
altern
introduc
posit
phenyl
moieti
previous
synthes
new
deriv
cytotox
evalu
cell
unluckili
relev
cytotox
show
mani
deriv
induc
group
dispos
acrylonitril
antitubercular
evalu
antiprolif
agent
report
nevertheless
benzotriazol
remain
interest
heterocycl
antimycobacteri
proprieti
variou
group
tri
combin
chemic
structur
within
well
known
antibacteri
agent
therefor
aim
develop
new
antitubercular
arylazetidinon
deriv
benzotriazol
prepar
convent
microwav
irradi
latter
outcom
best
perform
synthet
way
prepar
compound
show
cytotox
test
tb
microorgan
bacteria
fungi
result
compound
emerg
show
promis
activ
tb
mic
mgml
moreov
result
activ
bacteria
mic
mgml
escherichia
coli
fungi
mic
mgml
aspergillu
niger
fig
class
compound
select
action
report
dixit
et
al
use
linezolid
structur
basi
scaffold
creat
new
class
oxazolidinon
deriv
fig
perform
bioisoster
substitut
morpholin
moieti
benzotriazol
structur
ten
deriv
synthes
start
commerci
benzotriazol
antimycobacteri
activ
determin
suscept
sensit
strain
inhibit
two
front
line
antitb
drug
isoniazid
rifampicin
resist
strain
inhibit
either
isoniazid
rifampicin
ewa
group
present
seri
benzotriazol
deriv
work
base
consider
antimycobacteri
activ
revel
benzimidazol
deriv
modifi
heterocycl
core
exocycl
constitu
particularli
observ
biolog
activ
enhanc
introduct
nitrobenzylsulfenyl
group
posit
substitut
heterocycl
benzen
moieti
halogen
atom
complex
ihnresist
mott
mycobacterium
kansasii
strain
emerg
activ
refer
strain
mic
valu
compar
refer
drug
isoniazid
even
mycobacterium
kansasii
tb
isoniazideresist
moder
sensit
deriv
observ
appli
strategi
design
new
antitubercular
agent
normal
schedul
bioisoster
modif
know
structur
obtain
new
linear
deriv
perspect
except
repres
seri
angular
deriv
synthes
carta
et
al
structur
relat
quinolon
one
wide
prescrib
famili
synthet
antimicrobi
agent
particular
fluoroquinolon
fluorinecontain
deriv
older
quinolon
nalidix
acid
current
use
antitubercular
agent
mdrtb
infect
lesser
extent
case
sever
advers
reaction
convent
antitubercul
regimen
howev
still
classifi
secondlin
drug
sinc
use
tuberculosi
treatment
remain
controversi
behavior
justifi
fact
emerg
fluoroquinolon
resist
mdr
strain
possibl
even
appear
relat
poor
bactericid
activ
rapid
emerg
resist
dose
use
clinic
seen
ciprofloxacin
quinolon
mechan
action
pharmacokinet
wide
studi
variou
review
found
literatur
report
milata
review
carta
group
discov
triazolo
quinolon
carboxyl
acid
exhibit
interest
low
mic
valu
mg
ml
observ
also
activ
relat
length
posit
substitu
triazolenitrogen
compound
bear
methyl
group
show
higher
activ
first
observ
prompt
group
focal
work
design
select
synthes
seri
triazolo
quinolonecarboxyl
acid
fig
varieti
substitu
quinolon
nitrogen
introduc
aim
improv
biolog
activ
deriv
test
tb
clinic
isol
strain
endow
wide
spectrum
drug
resist
deriv
stood
potent
deriv
exhibit
mic
mgml
test
strain
latter
deriv
select
lead
compound
examin
human
macrophag
infect
tb
strain
success
grown
absenc
antitubercular
agent
presenc
lead
compound
macrophag
cultur
lyse
day
mycobacteri
growth
estim
cfuml
respect
untreat
cultur
grew
regularli
addit
supplementari
analysi
revel
good
antimycobacteri
activ
sever
mycobacterium
avi
paratuberculosi
mycobacterium
smegmati
mycobacterium
bovi
strain
modif
substitu
posit
ring
system
bulk
group
improv
biolog
activ
compar
new
deriv
previou
seri
methyl
group
confirm
effect
substitu
posit
lastli
mic
determin
panel
gramposit
gram
neg
bacteria
well
candida
sp
compound
result
inact
mic
mgml
new
class
quinolon
result
suggest
specif
antimycobacteri
potenti
behavior
probabl
due
differ
mechan
action
toward
quinolon
lead
good
candid
develop
potassium
channel
activ
repres
emerg
class
drug
treatment
nervou
respiratori
cardiovascular
disord
reason
repres
interest
research
topic
medicin
chemistri
field
literatur
benzimidazolon
pop
calciumdepend
potassium
channel
activ
molecul
abl
induc
vitro
cellular
hyperpolar
direct
activ
ca
activ
k
channel
bk
ca
channel
also
direct
inhibit
ca
channel
effect
contribut
vasorelax
properti
base
properti
baragatti
biagi
research
group
conduct
broad
studi
primarili
lead
design
synthesi
new
deriv
seri
correspond
seri
fig
seri
propos
bioisoster
analogu
benzotriazol
deriv
prove
possess
vasorelax
properti
potenc
paramet
lower
refer
compound
ns
abl
complet
break
contractil
tone
induc
administr
kcl
mm
rat
aorta
efficaci
contrast
benzimidazolon
compound
ineffect
inact
particularli
sar
studi
demonstr
absenc
substitu
benzotriazol
posit
caus
decreas
potenc
efficaci
contrari
methoxi
group
advers
affect
properti
furthermor
best
result
report
compound
bear
simpl
methyl
group
experiment
data
suggest
potenti
relationship
potenc
steric
hindranc
posit
final
benzotriazol
deriv
lack
carboxamido
group
posit
triazol
ring
total
powerless
vasorelax
agent
demonstr
conh
group
essenti
structur
requir
exert
vasorelax
effect
due
potassium
channel
bk
activ
consequ
analysi
carri
studi
effect
steric
hindranc
lipophil
due
substitu
posit
introduct
bulki
lipophil
group
secbutyl
phenyl
led
deriv
retain
equival
potenc
even
less
potent
deriv
bear
methyl
group
posit
fig
seri
ii
alongsid
deriv
prepar
benzotriazol
deriv
show
good
vasorelax
activ
full
efficaci
potenc
time
higher
triazolyl
benzotriazol
deriv
bear
h
atom
posit
activ
latter
compound
significantli
reduc
high
level
kcl
mm
suggest
possibl
pharmacodynam
profil
similar
drug
known
activ
potassium
channel
final
anoth
seri
benzotriazol
wherein
triazol
group
replac
hydroxybenzoyl
group
fig
seri
iii
prepar
therebi
thank
bridg
determin
carbonyl
function
new
molecul
ensur
greater
degre
freedom
therefor
flexibl
two
main
part
biolog
analysi
show
high
vasorelax
potenc
efficaci
deriv
howev
potent
deriv
set
one
bear
methyl
group
also
show
cardioprotect
properti
contrast
introduct
group
benzotriazol
ring
posit
replac
carbonyl
bridg
electron
withdraw
group
methylen
bridg
caus
consider
decreas
biolog
activ
cancer
actual
second
lead
caus
death
worldwid
cardiovascular
diseas
account
million
death
around
death
origin
tumor
lie
somat
cell
undergon
seri
genet
modif
thu
ceas
respond
normal
regulatori
mechan
oper
healthi
organ
thereaft
cell
prolifer
form
clone
neoplast
cell
character
lack
control
prolifer
concomitantli
cell
lose
potenti
replic
control
becom
immort
addit
mechan
densitydepend
inhibit
usual
allow
cell
multipli
reach
finit
cell
densiti
point
becom
quiescent
deactiv
tumor
classifi
benign
malign
depend
biolog
morpholog
characterist
determin
greater
lesser
aggress
common
cancer
lung
cancer
million
death
stomach
cancer
death
liver
cancer
death
colorect
cancer
death
breast
cancer
death
therapeut
approach
treatment
cancer
diseas
differ
includ
surgic
treatment
radiat
therapi
immunotherapi
chemotherapi
polychemotherapi
therefor
provid
use
virtual
toxic
drug
select
oper
respect
cancer
cell
thu
save
host
healthi
cell
unfortun
cell
similar
due
difficulti
discrimin
tumor
healthi
cell
drug
select
unattain
conclus
even
healthi
somat
cell
expos
toxic
effect
especi
continu
mitosi
hair
follicl
intestin
epithelium
bone
marrow
reason
research
new
molecul
abl
select
target
tumor
cell
still
activ
particularli
nitrogen
heterocycl
attract
attent
research
possibl
isoster
structur
compon
natur
nucleotid
also
bt
report
possibl
antiprolif
agent
principl
isoster
follow
zhan
lou
prepar
new
nucleosid
analogu
endow
antitumor
activ
previous
report
carbocycl
nucleosid
obtain
replac
oxygen
sugarch
group
stabl
enzymat
action
nucleosid
phosphorylas
also
equip
antitumor
activ
test
tumor
cell
line
deriv
human
lung
bladder
deriv
triazol
benzotriazol
substitut
activ
albeit
micromolar
level
shown
fig
alsoud
research
group
work
follow
principl
combin
potenti
activ
report
sever
alkyl
benzotriazol
triazol
nuclei
fig
start
carbonitril
prepar
azepin
compound
found
extrem
promis
biolog
evalu
analyz
perform
sever
human
tumor
cell
line
compound
stood
micromolar
activ
leukem
ccrfcem
gi
mm
ovarian
gi
mm
renal
gi
mm
tumor
cell
although
show
select
action
contrast
isom
result
inact
interest
gener
indoloquinolin
alkaloid
ie
cryptosanguinolentin
push
group
coordin
beauchard
design
prepar
seri
deriv
thiazol
ring
system
fuse
similar
polycycl
system
prepar
seri
new
naryl
thiazolobenzotriazol
synthesi
intermedi
evalu
potenti
anticanc
agent
start
thiazolebenzotriazol
compound
prepar
perform
substitut
nitrogen
quinolin
pyridin
nuclei
reactiv
cyano
group
benzothiazol
exploit
order
prepar
imidazolin
deriv
obtain
reaction
ethylenediamin
shown
fig
compound
substitut
n
test
two
cellular
line
deriv
breast
cancer
found
moder
activ
inhibit
deriv
resist
cell
line
except
compound
inact
line
gener
introduct
imidazolin
side
chain
determin
increas
biolog
activ
except
compound
final
group
wan
cowork
evalu
antiprolif
activ
new
benzotriazol
deriv
bmob
emerg
antiprolif
effect
cell
line
deriv
differ
tumor
type
molecul
therefor
use
order
defin
possibl
mechan
action
analys
carri
hepatocellular
carcinoma
cell
suscept
bmob
action
ic
mm
show
compound
led
cell
death
induct
collaps
mitochondri
membran
potenti
determin
product
reactiv
oxygen
speci
dna
fragment
exploit
concept
bioisoster
benzotriazolylpropiophenon
deriv
introduc
bulki
side
chain
reaction
nicotin
isonicotin
acid
nicotin
show
antitumor
activ
compound
b
fig
demonstr
potent
propag
inhibit
activ
liver
galactophor
cancer
cell
final
part
wide
studi
focus
benzotriazol
deriv
could
act
tb
carta
cowork
disclos
compound
belong
class
acrylonitril
abl
inhibit
cellular
prolifer
seri
liquid
solid
human
tumor
princip
research
identifi
e
acrylonitril
lead
compound
shown
fig
compound
time
potent
compar
etoposid
cell
line
similar
deriv
bear
benzotriazol
posit
electrondonor
substitu
methyl
group
result
absolut
devoid
efficaci
tumor
line
therefor
group
complet
sar
studi
introduc
posit
electronwithdraw
group
howev
synthes
deriv
e
acrylonitril
result
almost
devoid
activ
demonstr
introduct
chlorin
atom
benzotriazol
moieti
determin
consider
decreas
antiprolif
activ
class
compound
cell
cycl
analysi
also
reveal
seri
act
phase
cell
cycl
behavior
explain
possibl
interact
deriv
tubulin
cytoskeleton
protein
respect
microtubul
system
hypothesi
confirm
h
colchicin
competitionbind
scintil
proxim
assay
spa
one
benzotriazol
deriv
displac
strongli
colchicin
radiolabel
bind
site
tubulin
also
report
extend
molecular
model
studi
carri
use
model
tubulin
obtain
homolog
bo
tauru
btubulin
show
sequenc
homolog
human
one
fig
model
allow
thoroughli
studi
bind
site
molecular
interact
exist
acrylonitril
amino
acid
residu
bind
pocket
analysi
emerg
benzotriazol
ring
interact
tubulin
mainli
van
der
waal
interact
insert
triazol
moieti
insid
colchicin
bind
site
fig
consequ
compound
inhibit
tubulin
polymer
act
microtubul
destabil
agent
howel
et
al
show
preliminari
studi
small
set
deriv
depict
fig
compound
prepar
use
benzyneazid
click
chemistri
evalu
possibl
dna
intercal
antitumor
agent
unfortun
none
benzotriazol
deriv
show
appreci
displac
ethidium
displac
assay
mm
concentr
final
deriv
contain
benzotriazol
moieti
prepar
zhang
colleagu
potenti
antitumor
agent
biolog
target
identifi
focal
adhes
kinas
fak
nonreceptor
tyrosin
kinas
play
lead
role
cell
prolifer
among
compound
fig
stood
good
antiprolif
activ
cell
ic
mgml
also
best
fak
inhibitori
activ
ic
mm
compar
refer
drug
cisplatin
lead
compound
use
investig
probabl
action
mechan
cell
apoptosi
thought
bind
mode
analys
target
enzymeact
site
casein
kinas
pleiotrop
protein
highli
conserv
serinethreonin
tyrosin
kinas
constitut
activ
involv
numer
metabol
process
believ
involv
cell
growth
healthi
cancer
cell
synthesi
trna
mrna
well
apoptosi
cell
transform
describ
first
time
burnett
kennedi
differ
isoform
identifi
howev
convent
exist
either
form
tetramer
complex
compos
two
catalyt
subunit
two
regulatori
subunit
b
b
free
subunit
also
indic
tetramer
assembl
complex
structur
increas
evid
suggest
differ
molecular
form
may
involv
differ
cellular
activ
instanc
substrat
phosphoryl
tetramer
other
phosphoryl
exclus
free
catalyt
subunit
also
protein
abl
interact
identifi
discrimin
tetramer
individu
subunit
scientif
literatur
demonstr
antiapoptot
properti
abl
interfer
import
compon
cell
surviv
pathway
especi
determin
downregul
proapoptot
protein
caspas
paper
shown
evolut
neoplast
diseas
cancer
onset
directli
proport
activ
furthermor
demonstr
show
oncogen
activ
transgen
mice
frequent
overexpress
tumor
leukemia
cell
final
high
constitut
activ
suspect
contribut
pathogen
potenti
sinc
exploit
sever
virus
exert
phosphoryl
protein
essenti
life
cycl
furthermor
catalyt
subunit
cooper
protooncogen
promot
cell
transform
differ
experiment
model
make
attract
target
search
new
antineoplast
antivir
agent
recent
year
potent
select
inhibitor
develop
among
sarno
cowork
show
tbbt
select
specif
inhibitor
far
analys
among
protein
kinas
test
research
group
three
inhibit
tbbt
ic
valu
appear
two
order
magnitud
higher
valu
calcul
use
three
kinas
inhibit
tbbt
belong
protein
kinas
subfamili
name
cmgc
group
phk
belong
camk
group
moreov
within
ck
famili
tbbt
turn
select
ki
mm
comparison
ki
mm
third
class
ck
protein
local
golgi
apparatu
instead
total
unrespons
tbbt
evid
suggest
tbbt
possess
particular
select
toward
inhibitor
agent
behavior
combin
molecular
abil
penetr
insid
cell
lack
evid
short
term
cytotox
made
tbbt
promis
lead
design
new
compound
high
therapeut
potenti
zien
research
group
compar
activ
tbbt
tbbi
toward
purifi
holoenzym
show
latter
far
effect
discrimin
differ
form
present
yeast
also
dramat
effect
induct
apoptosi
lesser
extent
necrosi
transform
human
cell
moreov
solut
complex
crystal
structur
allow
comparison
analogu
complex
lead
conclus
despit
structur
similar
molecul
bound
biolog
target
quit
differ
manner
histori
tbbt
born
demonstr
fig
repres
key
constitu
vitamin
b
observ
stimul
synthesi
variou
structur
analogu
evalu
biolog
activ
particularli
cell
prolifer
discov
bdribofuranosyl
benzimidazol
drb
abl
inhibit
vitro
vivo
mrna
synthesi
eukaryot
cell
addit
demonstr
potent
inhibitor
vitro
vivo
transcript
concomitantli
inhibit
purifi
activ
time
lower
concentr
drb
work
motiv
studi
halogen
benzimidazol
nucleosid
analogu
led
eventu
synthesi
tbbt
inhibitor
specif
tbbt
exploit
extens
understand
function
research
group
battistutta
instanc
studi
interact
tbbt
zea
may
protein
kinas
catalyt
subunit
particularli
delin
enzymeeinhibitor
complex
crystal
structur
specif
select
tbbt
appear
mainli
direct
reduc
size
activ
site
small
hydrophob
pocket
adjac
atpgtp
bind
site
tbbt
perfectli
fit
depict
fig
main
interact
tbbt
hydrophob
natur
involv
four
bromin
atom
halogen
size
allow
tbbt
perfect
insert
caviti
concomitantli
releas
inhibitor
trap
insid
pocket
inhibitori
power
decreas
tbbt
four
bromin
atom
replac
smaller
atom
instanc
chlorin
atom
previous
observ
szyszka
research
group
therefor
tbbt
lose
inhibitori
potenc
major
protein
kinas
protein
kinas
hydrophob
bind
site
gener
larg
gener
stabl
interact
inhibitor
relev
individu
bromin
atom
tbbt
investig
group
wasik
synthes
possibl
tbbt
isom
mono
four
di
two
tribromobenzotriazol
prepar
physicochem
properti
evalu
aqueou
medium
analysi
confirm
hydrophob
electrostat
interact
predomin
fulli
halogen
benzotriazol
determin
select
inhibit
protein
kinas
order
increas
tbbt
tbbi
activ
inhibitor
research
group
bretner
najdabernatowicz
design
new
tetrabromin
deriv
evalu
influenc
tbbttbbi
inhibitori
potenc
tbbttbbi
deriv
bear
alkyl
substitu
differ
hydrophob
steric
electrophil
featur
research
program
base
evid
water
molecul
necessari
enzymat
activ
coordin
bind
site
molecul
could
displac
similar
substitu
new
nhydroxyalkyl
deriv
test
human
holoenzym
b
evid
demonstr
pharmacolog
activ
depend
alkyl
chain
length
nhydroxyalkyl
deriv
show
ic
valu
similar
parent
compound
best
result
ensur
chain
ic
valu
mm
group
investig
effect
bulkier
alkyl
chain
hydrophob
polar
properti
appear
best
seri
small
differ
deriv
fig
contrari
deriv
bear
shorter
longer
alkyl
chain
drastic
decreas
activ
observ
addit
demonstr
four
bromin
atom
benzen
ring
seem
essenti
requir
biolog
activ
inde
substitut
bromin
chlorin
ch
group
lead
significantli
lower
inhibitori
effect
versu
differ
form
human
relev
triazol
system
final
underlin
replac
phthalimid
moieti
featur
present
mani
biolog
activ
compound
phthalazin
system
inde
deriv
thu
obtain
result
powerless
research
group
continu
design
new
tbbt
deriv
consider
fact
hypothesi
concern
small
size
tbbt
bind
site
fade
year
especi
light
biolog
success
report
larger
molecul
new
research
led
deriv
bear
triazol
moieti
even
bulkier
side
chain
modif
tetrabromin
benzen
ring
also
evalu
two
bromin
atom
replac
aryl
alkyl
substitu
unfortun
comparison
tbbt
ic
mm
increas
activ
observ
compound
except
ic
mm
ic
mm
shown
fig
swider
group
synthes
new
benzotriazol
deriv
use
receptorbas
design
approach
obtain
compound
abl
interact
simultan
mg
chelat
residu
proteinsubstr
bind
residu
compound
obtain
azidealkyn
huisgen
cycloaddit
tetrabromobenzotriazol
deriv
result
combin
tetrahalogen
moieti
nice
occupi
atpbind
site
side
chain
abl
bind
simultan
enzymat
activ
site
basic
residu
particip
protein
substrat
bind
like
similar
bisubstr
inhibitor
kinas
paper
report
preliminari
nonoptim
result
activ
compound
ic
mm
synthesi
report
fig
final
import
report
new
synthet
approach
wawro
cowork
base
two
consider
first
none
previous
synthes
halogen
deriv
tbbt
chiral
center
second
presenc
stereocent
close
polar
group
ie
oh
could
led
differ
inhibitori
activ
two
enantiom
base
consider
take
refer
hydroxyalkyl
deriv
synthes
nadjabernatowicz
makowska
group
develop
new
synthet
approach
isol
enantiopur
hydroxyalkyl
deriv
tbbt
fig
obtain
optic
activ
compound
endow
enantioselect
factor
e
molecul
potenti
inhibitor
might
use
synthes
new
optic
pure
tbbt
deriv
benzotriazol
form
complex
differ
transit
metal
studi
n
azol
deriv
involv
coordin
complex
transit
metal
highlight
potenti
anticanc
properti
basi
group
saczewski
report
synthesi
biolog
evalu
chelat
bident
benzotriazol
copper
ii
complex
also
design
new
molecul
idea
creat
compound
endow
potenti
copperezincsuperoxid
dismutas
cu
znsod
mimick
activ
accord
theori
oberley
buettner
sod
activ
tumor
cell
lower
found
normal
cell
complex
show
lower
higher
sod
activ
respect
sinc
compound
differ
substitut
posit
benzotriazol
ring
follow
biolog
activ
exquisit
sensit
structur
coordin
ligand
fig
deriv
substitut
show
potent
vitro
sod
activ
mm
ic
valu
compar
data
report
literatur
mimick
sod
agent
evalu
vitro
cytotox
seven
tumor
line
deriv
substitut
turn
best
one
record
ic
valu
mm
histon
deacetylas
hdac
enzym
catalyz
remov
acetyl
group
lysin
residu
especi
histon
chemic
modif
key
step
gene
express
regul
influenc
cell
differenti
prolifer
process
abnorm
hdac
function
link
carcinogenesi
process
fact
mani
hdac
inhibitor
exert
vivo
antitumor
effect
human
hdac
gener
divid
four
class
accord
homolog
yeast
hdac
subcellular
local
enzymat
activ
class
includ
class
ii
compos
six
member
class
iii
also
known
sirtuin
includ
nad
depend
enzym
class
iv
includ
properti
hdac
class
class
ii
hdac
inhibitor
classifi
five
group
accord
chemic
structur
hydroxam
acid
cyclic
tetrapeptid
apicidin
short
chain
carboxyl
acid
valproic
acid
benzamid
ketoacid
howev
recent
paper
fu
cowork
even
benzotriazol
deriv
recogn
antiprolif
agent
exert
biolog
action
hdac
inhibit
group
synthes
variou
benzotriazol
compound
bear
substitut
benzoic
acid
antitumor
activ
evalu
three
differ
human
tumor
cell
line
compound
show
moder
antiprolif
activ
except
compound
stood
ic
valu
nm
close
posit
control
doxorubicin
sar
analysi
emphas
relev
och
group
antiprolif
activ
fact
deriv
bear
substitu
benzoic
ring
posit
power
methoxyl
substitut
benzotriazol
group
result
drastic
reduct
antiprolif
activ
hdac
inhibitori
activ
determin
use
hela
nuclear
extract
enzym
sourc
take
trichostatin
tsa
suberoylanilid
hydroxam
acid
hsa
refer
drug
analyz
quantit
experiment
result
obtain
clear
potent
deriv
trimethoxi
deriv
agreement
antiprolif
activ
result
deriv
final
subject
molecular
dock
studi
simul
interact
hdac
use
autodock
softwar
analysi
highlight
hydrophob
interact
benzotriazol
phenyl
moieti
enzymat
bind
pocket
fig
three
dimension
quantit
structureeact
relationship
addit
molecular
dock
studi
class
compound
perform
obtain
inform
ration
design
novel
benzotriazol
endow
potent
antiprolif
activ
peroxisom
proliferatoractiv
receptor
ppar
belong
superfamili
intracellular
receptor
regul
mani
biolog
process
includ
energi
metabol
glucos
lipid
metabol
cell
prolifer
skin
develop
inflammatori
process
pparg
member
steroid
nuclear
receptor
superfamili
second
class
regul
gene
transcript
format
function
heterodim
retinoid
x
receptor
rxr
acid
ppar
rxr
complex
modul
express
target
gene
recogn
specif
respons
sequenc
consist
direct
repeat
dr
hexanucleotid
sequenc
act
ct
separ
singl
nucleotid
ppar
subfamili
includ
three
isoform
bd
g
encod
differ
gene
ppara
pparg
identifi
specif
ligand
consist
satur
polyunsatur
longchain
fatti
acid
eicosanoid
hypolipidem
agent
particular
among
ppara
agonist
rememb
fenofibr
gemfibrozil
bezafibr
clofibr
develop
drug
treatment
dyslipidemia
pioglitazon
rosiglitazon
agonist
pparg
develop
drug
treatment
type
diabet
mellitu
howev
neither
fibrat
glitazon
abl
simultan
lower
triglycerid
glucos
blood
level
therefor
ppar
agonist
research
thu
ever
time
use
treatment
dyslipidem
patient
suffer
type
diabet
accord
studi
conduct
sparator
research
group
mani
ppar
agonist
possess
three
key
region
acid
head
thiazolidinedion
ring
alkanoyl
residu
b
linker
portion
benzen
ring
bear
various
function
chain
para
posit
head
c
hydrophob
tail
form
monoor
polycycl
aromat
heteroaromat
moieti
rosiglitazion
fig
thu
develop
new
ppar
bd
g
activ
sparator
et
al
decid
stiffen
last
two
part
suppress
flexibl
chain
linker
aromat
ring
new
seri
phenoxi
alkano
acid
synthes
phenoxi
moieti
character
compound
also
present
dimethylamino
propoxi
phenyl
latter
recogn
abl
significantli
reduc
cholesterol
level
hypercholesterolem
mice
measur
compar
bezafibr
undergo
biolog
test
studi
show
compound
phenoxi
acid
acid
dual
activ
ppar
ad
ppar
ag
respect
possess
effect
equal
refer
compound
differ
strongli
potenc
present
respect
ec
interestingli
dimethylamino
propoxi
phenyl
found
inact
three
receptor
concentr
mm
demonstr
probabl
lipidlow
effect
molecul
due
differ
mechan
action
summari
obtain
result
show
phenoxi
moieti
character
compound
repres
new
scaffold
synthesi
potenti
ppar
agonist
treatment
dyslipidemia
associ
type
diabet
niddm
particular
kind
dyslipidemia
associ
diabet
well
known
neurotransmitt
simpli
call
serotonin
implic
sever
physiolog
function
includ
appetit
control
mood
regul
voluntari
movement
circadian
cycl
bodi
temperatur
attent
memori
learn
alter
serotonerg
system
may
induc
psychiatr
disord
anxieti
depress
obsessivecompuls
disord
reason
recent
year
dopamin
serotonin
agonist
antagonist
administ
treatment
schizophrenia
parkinson
diseas
caliendo
research
group
report
seri
r
alkyl
benzotriazol
deriv
design
structur
analogu
trazodon
known
psychoact
drug
belong
piperazin
triazolopiridin
class
synthes
deriv
fig
contain
three
major
structur
substitut
piperazin
ring
cyclic
system
contain
unsubstitut
benzotriazol
nucleu
alkyl
alkyloxi
linker
act
linker
piperazin
benzotriazol
moieti
first
seri
r
propyl
benzotriazol
prepar
deriv
screen
vitro
antiserotonin
antiadrenerg
antihistaminerg
effect
well
vivo
analges
activ
concern
antiserotonin
activ
result
show
deriv
power
isom
compound
bear
nitrogen
unsubstitut
phenyl
ring
stood
potenc
aim
broaden
structureeact
relationship
sar
class
analogu
group
synthes
new
seri
compound
shorten
modifi
alkyl
bridg
benzotriazol
ring
piperazin
nitrogen
particularli
replac
propylen
linker
ethylen
oxypropylen
moieti
set
r
ethyl
benzotriazol
set
r
prepar
screen
power
deriv
belong
r
ethylbenzotriazol
seri
deriv
bear
alkyl
substitu
nitrogen
h
show
none
extrem
low
activ
moreov
introduct
chlorin
atom
ortho
meta
posit
phenyl
ring
determin
increas
activ
contrari
substitut
para
posit
determin
loss
time
still
introduct
methylen
ethylen
bridg
aromat
ring
piperazin
nucleu
led
activ
decreas
due
steric
electron
effect
rather
hydrophob
effect
vivo
noradrenalineinduc
va
defer
contract
inhibit
investig
determin
antiadrenerg
activ
deriv
substitut
benzotriazol
bear
piperidin
moieti
phenyl
chlorophenyl
result
activ
antihistamin
effect
instead
determin
compound
bear
simultan
side
chain
oxypropylen
bridg
aromat
moieti
substitut
aryl
benzyl
group
methyl
bhydroxyethyl
chain
led
signific
activ
reduct
caliendo
group
bind
assay
radiolabel
ligand
assay
highlight
affin
previous
synthes
deriv
newli
synthes
compound
j
recombin
human
receptor
subtyp
experiment
result
show
compound
possess
high
affin
receptor
none
bore
affin
subtyp
bond
receptor
favor
group
ph
piperazin
ring
instead
receptor
potenc
increas
significantli
substitu
oph
locat
piperazin
ring
final
author
deduc
differ
receptor
bind
affin
due
doubl
effect
r
substitu
type
carbon
linker
evid
justifi
differ
mode
interact
ligand
receptor
postul
ismaiel
et
al
caliendo
research
group
also
compar
bind
affin
select
deriv
differ
receptor
isoform
express
ratio
best
select
ratio
obtain
r
ph
group
contrari
r
oph
group
deriv
act
antagonist
potenti
receptor
ligand
trazodon
like
compound
report
sparator
et
al
analyz
benzotriazol
pharmaceut
properti
long
time
group
prepar
seri
propoxi
phenyl
noxid
design
base
previou
biolog
evid
report
seri
dialkylaminoalkoxi
phenyl
benzotriazol
correspond
noxid
seri
depict
fig
inde
arylheteroaryl
moieti
wellknown
ligand
receptor
affin
deriv
dopamin
adrenerg
receptor
exclud
compound
abl
bind
dopamin
receptor
well
serotonin
receptor
howev
present
low
affin
subtyp
particularli
compound
contain
residu
noxid
function
definit
activ
ki
nm
contrari
noxid
benzotriazol
ring
exert
neg
influenc
affin
receptor
phenyl
noxid
show
affin
receptor
affin
increas
length
aliphat
linker
obtain
deriv
methylen
bridg
exhibit
good
excel
select
final
propyl
piperazin
instead
identifi
potent
receptor
antagonist
preand
postsynapt
receptor
paluchowska
cowork
highlight
relev
aliphat
linker
length
methoxi
phenyl
piperazin
moieti
nucleu
fig
synthes
evalu
seri
aryl
piperazin
linker
compos
two
four
methylen
group
part
set
prove
act
ligand
receptor
ki
nm
deriv
bimethylen
bridg
result
inact
vivo
tetramethylen
bridg
prove
oper
antagonist
postsynapt
receptor
arylheteroarylpiperazinyl
alkyl
benzotriazol
fig
prepar
evalu
modif
benzotriazol
moieti
introduct
substitu
cl
och
aryl
side
chain
introduct
group
aim
modif
increas
affin
deriv
receptor
fact
new
compound
demonstr
moder
good
affin
serotonin
receptor
wherea
none
modest
affin
dopamin
receptor
particularli
affin
compound
h
g
l
higher
trazodon
often
compar
buspiron
final
confirm
relev
previous
descript
structur
report
failur
trifluoromethyl
methoxyphenyl
deriv
b
depict
fig
came
complet
inact
competitor
sparator
group
describ
seri
benzotriazolylalkano
acid
benzotriazollyl
butano
acid
fig
emerg
strong
choleret
activ
therefor
seri
structur
chang
carri
order
understand
mean
modif
heterocycl
aromat
moieti
result
demonstr
introduct
methyl
methoxi
group
benzotriazol
posit
caus
biolog
activ
decreas
comparison
benzotriazollyl
butano
acid
presenc
trifluoromethyl
group
increas
side
chain
modif
benzotriazol
nitrogen
also
consequ
activ
maintain
introduc
unsatur
nalkyl
chain
lost
shorten
deriv
antinocicept
antiinflammatori
activ
evalu
propion
acid
exhibit
signific
activ
anti
inflammatori
antinocicept
agent
seri
acid
fig
synthes
templat
acid
identifi
highthroughput
screen
agonist
receptor
predominantli
express
human
adipocyt
mediat
antilipolyt
effect
compound
biolog
activ
measur
use
camp
wholecel
assay
act
agonist
significantli
lower
activ
report
cycloalkylsubstitut
deriv
except
cyclopentyl
deriv
addit
compound
show
excel
select
vs
none
determin
activ
homolog
mous
receptor
pumag
bioisoster
modif
carboxyl
moieti
tetrazol
motif
done
explor
limit
bind
pocket
none
compound
activ
assay
suggest
enlarg
molecular
acid
region
could
toler
research
synthes
mani
alkanoyl
acid
includ
seri
phenoxi
alkano
acid
noxid
endow
differ
biolog
properti
antiinflammatori
diuret
antihypertens
year
addit
modif
done
base
buuhoi
studi
substitut
benzimidazol
phenyl
benzimidazol
exhibit
noxid
synthes
describ
fig
pharmacolog
investig
demonstr
compound
show
differ
behavior
prevent
hypoxiainduc
death
mice
treat
potassium
cyanid
effect
normal
exercis
calcium
antagonist
cinnarizin
flunarizin
effect
may
relat
antagon
versu
leukotrien
receptor
effect
exhibit
deriv
inhibit
thromboxan
exert
compound
latter
show
also
antiatherogen
properti
diuret
action
exert
compound
strongli
cholesterollow
activ
deriv
wide
use
synthes
new
compound
pharmaceut
interest
benzotriazol
mention
far
stand
multipl
biolog
activ
includ
antiinflammatori
anesthet
anticonvuls
activ
fig
antiinflammatori
diuret
analges
antihypertens
activ
evalu
obtain
good
result
one
area
instead
compound
n
tertamino
ethyl
n
lupinyl
acetamid
assess
local
anesthet
show
activ
compar
higher
lidocain
benzotriazol
ring
also
combin
tetrazol
system
order
enhanc
antinocicept
antiinflammatori
properti
nuclei
among
report
ethyl
triazol
deriv
compound
fig
emerg
antinocicept
properti
abl
tripl
quadrupl
respect
reaction
time
hot
plate
test
instead
compound
antiinflammatori
activ
superior
deriv
seri
fig
final
compound
evalu
vitro
antibacteri
antifung
anticonvuls
activ
obtain
result
show
moder
protect
seizur
best
result
report
compound
among
new
deriv
fit
categori
nonsteroid
antiinflammatori
agent
compound
obtain
combin
benzotriazol
benzofuran
nucleu
later
antinocicept
antiinflammatori
activ
evalu
pchlorophenyl
pyrazol
stood
analges
action
sar
studi
show
pyrazol
nucleu
effect
ring
result
obtain
sever
anim
model
suggest
deriv
exert
central
peripher
mediat
antinocicept
properti
almost
prepar
compound
also
express
antiinflammatori
activ
maximum
ethanon
sar
analysi
deriv
demonstr
activ
decreas
modif
phenyl
side
chain
final
studi
mechan
action
show
new
compound
act
select
inhibit
anticonvuls
activ
check
select
compound
similarli
refer
drug
valproic
acid
deriv
b
found
activ
subcutan
metrazol
scmet
test
howev
deriv
activ
maxim
electroshock
seizur
me
test
similarli
second
refer
compound
phenytoin
none
act
third
refer
compound
carbamazepin
activ
me
scmet
test
structur
depict
fig
virus
pathogen
caus
major
diseas
human
anim
determin
life
lost
econom
loss
higher
product
cost
bartorfd
classif
part
dna
rna
virus
mani
biolog
target
antivir
compound
like
would
success
identifi
crucial
metabol
enzym
polymeras
proteas
helicas
repres
attract
target
drug
discoveri
nucleosid
nonnucleosid
inhibitor
wide
investig
implement
pharmacolog
arsen
obtain
potent
select
antivir
agent
sever
benzotriazol
deriv
act
antivir
agent
show
sometim
interest
select
action
synthesi
biolog
activ
benzotriazol
analog
ntpasehelicas
inhibitor
extens
investig
recent
report
ntpasehelicas
promis
target
posit
sens
singlestrand
rna
enzym
studi
detail
ssrna
virus
belong
flavivirida
picornavirida
famili
continu
pose
threat
public
health
benzotriazol
helicas
inhibitor
repres
interest
class
drug
potent
deriv
identifi
cours
random
screen
studi
particularli
previous
report
inhibitor
tbbt
bdribofuranosyl
benzotriazol
drbt
display
antivir
activ
show
ic
valu
mm
respect
drbt
tbbt
test
four
differ
hcv
subgenom
replicon
system
result
abl
inhibit
hcv
replic
ec
drbt
mm
ec
tbbt
mm
compar
way
inhibit
report
enzymat
essay
show
properti
detect
hand
group
hcv
inhibitor
moreov
cytotox
concentr
mm
furthermor
nalkyl
deriv
tbbt
show
good
inhibitori
activ
hcv
wnv
jev
ntpasehelicas
less
cytotox
benzotriazol
moieti
relev
final
demonstr
replac
benzimidazol
bdribofuranosyl
benzimidazol
drb
dbrb
much
less
potent
hcv
helicas
inhibitor
fig
explain
behavior
bretner
et
al
synthes
studi
new
seri
nsubstitut
start
compound
show
low
anti
hcvhelicas
activ
dna
substrat
ic
mm
mm
respect
activ
ic
mm
measur
either
rna
substrat
enzym
wnv
denv
jev
flavivirida
famili
contrari
whole
bromin
reveal
fold
effect
hcv
helicas
inhibitor
determin
rna
dna
substrat
potenc
case
jev
helicas
ic
mm
moreov
bromin
result
less
effici
tbbt
potent
nonhalogen
parent
compound
hcv
helicas
enhanc
hydrophob
nalkyl
deriv
substitut
methyl
ethyl
propyl
moieti
synthes
shown
fig
comparison
benzotriazol
effect
hcvhelicas
use
dna
substrat
demonstr
deriv
result
significantli
potent
helicas
inhibitor
benzotriazol
benzimidazol
aliphat
chain
elong
determin
activ
enhanc
howev
benzimidazol
deriv
inhibitori
activ
low
dna
substrat
rang
mm
ineffici
rna
substrat
well
use
viral
ntpase
helicas
behavior
suggest
inhibitor
act
block
enzymat
ntp
bind
site
previous
suggest
porter
occup
alloster
nucleosid
bind
site
consid
investig
role
hydrophob
nalkyl
substitu
author
observ
replac
alkyl
sidechain
substitu
endow
higher
hydrophil
hydroxyethyl
deriv
higher
hydrophob
chloroethyl
deriv
sever
decreas
activ
tbbt
deriv
demonstr
small
hydrophob
alkyl
moieti
methyl
ethyl
tbbt
posit
could
play
crucial
role
hcv
ntpasehelicas
inhibit
final
introduct
ribofuranosyl
ring
benzotriazol
tetrabromobenzotriazol
improv
water
solubl
led
inhibitori
activ
decreas
inhibitori
activ
hcv
test
enzym
benzotriazol
investig
carta
cowork
evalu
vitro
cytotox
antivir
activ
wide
spectrum
ssrna
virus
seri
n
yl
phenyl
alkylcarboxamid
enterovirus
picornavirida
famili
virus
inhibit
mention
compound
particularli
picornavirus
repres
interest
target
explor
sinc
actual
specif
antivir
therapi
avail
treatment
picornavirida
infect
two
compound
emerg
select
n
phenyl
acetamid
activ
ec
mm
cc
mm
n
trifluoromethyl
phenyl
acetamid
activ
ec
mm
cc
mm
fig
sar
analysi
suggest
potenc
select
compound
probabl
due
small
electrondonor
methyl
group
posit
phenyl
group
posit
propanoylamid
group
side
select
compound
correl
cf
group
posit
phenyl
posit
amid
group
compound
also
evalu
silico
polio
viru
helicas
model
obtain
homolog
techniqu
molecular
dynam
simul
show
inhibitor
abl
rank
bind
affin
similar
dock
mode
put
bind
site
fig
use
molecul
lead
compound
make
use
diana
patent
concern
n
nbi
phenyl
alkyldicarboxamid
carta
et
al
prepar
seri
n
nbi
yl
phenyl
alkyldicarboxamid
evalu
parallel
cellbas
assay
cytotox
antivir
activ
repres
picornavirida
flavivirida
none
deriv
result
activ
repres
rna
virus
contrari
best
activ
report
analogu
among
exhibit
good
activ
enterovirus
ec
mm
ec
mm
final
deriv
emerg
interest
select
activ
ec
mm
total
inact
virus
screen
fig
final
extend
bind
mode
studi
perform
helicas
model
previous
obtain
homolog
techniqu
furthermor
absenc
helicas
model
activ
deriv
explain
adopt
align
analysi
benzotriazol
deriv
also
found
interest
proteas
inhibitor
toward
new
break
human
coronaviru
sever
acut
respiratori
syndrom
coronaviru
sarscov
spread
southern
china
late
sar
becam
epidem
rapidli
spread
origin
countri
affect
almost
patient
caus
death
infect
reach
high
mortal
rate
sinc
effect
anticoronavirus
therapeut
avail
consid
linger
danger
human
health
repres
sarscov
well
coronavirus
look
help
sarscov
antivir
actual
focal
point
import
enzymat
target
scientif
commun
identifi
repres
proteas
main
proteinas
pro
also
call
dimer
chymotrypsinlik
proteas
pro
enzym
cleavag
two
polyprotein
provid
function
protein
viral
propag
pro
inhibitor
report
like
aryl
boron
acid
ketoglutamin
analogu
phtalhydrazid
keton
bepoxyketon
thiopurin
analogu
wu
colleagu
report
new
class
stabl
benzotriazol
ester
appear
act
pro
irrevers
inactiv
inhibit
constant
nanomolar
rang
deriv
obtain
use
strategi
combinatori
reaction
microtit
plate
follow
situ
screen
particularli
benzotriazol
ester
prepar
condens
hexafluorophosph
hbtu
variou
carboxyl
acid
deriv
result
stabl
ph
h
room
temperatur
screen
compound
cytotox
cc
vero
cell
mm
acid
ester
fig
stood
exhibit
k
inact
k
nm
extens
mode
action
studi
suggest
benzotriazol
ester
could
determin
inhibit
pro
via
irrevers
acyl
shown
fig
particularli
essenti
proteas
activ
site
act
princip
catalyt
residu
cystein
thiol
oper
nucleophil
proteolyt
process
howev
even
though
regist
ki
valu
among
lowest
inhibitor
sarscov
pro
describ
far
author
also
report
full
inhibit
enzym
could
achiev
final
addit
benzotriazol
ester
propos
paper
develop
obtain
stabl
deriv
ester
oxygen
replac
carbon
atom
unfortun
result
weaker
correspond
ester
bind
noncoval
enzym
verschueren
et
al
studi
bind
mode
benzotriazol
ester
sarscov
main
proteinas
use
two
compound
benzoyloxi
benzotriazol
benzotriazol
deriv
structur
depict
fig
abl
inhibit
enzymat
activ
low
micromolar
concentr
mm
mm
respect
author
demonstr
benzotriazol
ester
act
suicid
inhibitor
coval
bind
proteinas
notabl
librari
inhibitor
base
halopyridinyl
ester
compound
fig
abl
complet
inhibit
hepat
viru
hav
pro
nanomolar
concentr
far
benzotriazol
deriv
individu
ssrna
virus
inhibitor
howev
almost
one
singlestrand
neg
strand
rna
viru
identifi
target
compound
bear
benzotriazol
moieti
human
respiratori
syncyti
viru
rsv
classifi
genu
pneumoviru
paramyxovirida
famili
rsv
lead
caus
acut
respiratori
tract
infect
age
peopl
also
caus
seriou
lower
respiratori
tract
infect
infant
younger
month
infant
born
week
gestat
infant
children
underli
lung
diseas
congenit
heart
diseas
elderli
immunocompromis
person
sever
infect
viru
may
result
bronchiol
pneumonia
may
requir
hospit
result
death
world
health
organ
estim
rsv
caus
million
infect
death
annual
current
ribavirin
approv
treatment
viral
infect
other
emergingneglect
viral
infect
efficaci
remain
controversi
therefor
still
mandatori
identifi
effect
therapeut
option
treat
rsv
infect
atrisk
popul
perspect
colloc
paper
written
yu
cowork
group
report
dialkylamino
alkyl
methyl
benzimidazol
new
class
inhibitor
abl
protect
human
lung
carcinoma
cell
line
cell
rsv
cytopath
effect
inde
compound
protect
bristolmy
squibb
compani
patent
part
firstli
disclos
pagani
paglietti
found
poss
analges
antiarythm
activ
lead
compound
first
seri
depict
fig
sar
analysi
center
variat
dialkylaminoalkyl
side
chain
wide
toler
structur
variat
observ
polar
lipophil
group
termin
chain
terminu
preserv
rsv
inhibit
howev
requir
minimum
two
atom
separ
terminu
heterocycl
moieti
author
also
establish
topolog
relationship
benzotriazol
respect
substitut
benzoimidazol
moieti
critic
sinc
isom
proprieti
equal
unfortun
review
broad
survey
design
delin
pharmacophor
associ
lead
compound
guid
yu
et
al
replac
benzotriazol
modif
led
even
potent
antirsv
agent
howev
tonelli
et
al
extend
analysi
methyl
benzimidazol
accord
report
bristol
research
evalu
antivir
activ
relat
methyl
benzimidazol
firstli
prepar
group
examin
yu
et
al
particular
deriv
well
compound
bear
posit
simpl
dialkylamino
alkyl
chain
bulki
strongli
basic
lipophil
quinolizidinyl
alkyl
nucleu
lupinyl
epilupinyl
homolupinyl
reor
synthes
deriv
depict
fig
total
fortythre
methyl
benzimidazol
test
cytotox
antivir
activ
larg
panel
rna
dna
virus
among
thirtynin
compound
exhibit
potent
activ
rsv
case
ec
valu
nm
sar
studi
suggest
presenc
substitu
benzimidazol
posit
led
increas
cytotox
especi
compound
bear
quinolizidinyl
alkyl
nucleu
toward
antivir
activ
potent
compound
carri
chlorin
atom
posit
pair
r
equal
ch
n
ch
ch
n
ch
contrari
replac
cl
h
cf
coch
led
potenc
reduct
surpris
introduct
r
bulkier
group
led
progress
increas
potenc
seen
ch
n
ch
replac
ch
n
ch
ch
lupinyl
group
homolupinyl
deriv
potent
regardless
whether
r
h
cl
final
n
substitut
benzotriazol
gener
less
activ
n
substitut
isom
diabet
mellitu
type
formerli
noninsulindepend
diabet
mellitu
niddm
adultonset
diabet
metabol
disord
carbohydr
metabol
character
high
blood
glucos
level
due
defect
insulin
secret
insulin
resist
avail
antihyperglycem
agent
actual
burden
signific
side
effect
thu
urgent
need
develop
new
therapeut
agent
promis
biolog
target
identifi
protein
tyrosin
phosphatas
act
neg
regul
insulin
signal
patchway
year
protein
structur
elucid
inhibitor
abl
bind
know
activ
site
identifi
puiu
colleagu
identifi
even
addit
non
catalyt
aryl
phosphat
bind
site
consequ
new
inhibitor
abl
bind
across
site
b
design
synthes
aim
identifi
new
inhibitor
abl
bind
site
b
seri
benzotriazol
deriv
contain
difluoromethylphoshon
dfmp
moieti
synthes
compound
fig
emerg
inhibitori
activ
nanomolar
level
ic
nm
respect
moreov
crystallograph
analysi
demonstr
act
dualinhibitor
exhibit
moder
select
close
relat
tcell
protein
tyrosin
phosphatas
tcptp
mutagenesi
data
confirm
find
class
benzotriazol
deriv
even
studi
carri
analysi
result
highlight
relev
hydrogen
bond
form
arg
benzotriazol
moieti
class
select
novel
tetrasubstitut
benzotrazolebas
inhibitor
fig
contain
dfmpsubstitut
naphthyl
templat
prepar
patel
colleagu
compound
contain
key
structur
compon
benzotriazol
ring
obtain
superior
select
b
acetophenon
c
benzyl
naphthyl
quinolinyl
ring
system
suitabl
substitut
difluoromethylsulfonamid
dfm
improv
lipophil
oral
efficaci
final
dfmpsubstitut
naphthyl
quinolinyl
deriv
obtain
compound
bear
two
dfmp
group
abl
access
bind
site
b
therebi
improv
potenc
select
tcptp
best
result
obtain
compound
show
excel
antihyperglycem
effect
anim
model
improv
oral
bioavail
along
excel
select
tcell
protein
tyrosin
phosphatas
tcptp
phenyl
benzotriazol
deriv
fig
identifi
environment
pollut
endow
mutagen
activ
salmonella
consid
genotox
compound
may
play
role
develop
variou
diseas
cancer
sar
analysi
pbta
show
compar
mutagen
highlight
relev
primari
amino
group
along
planar
ring
halogen
group
potenti
damag
effect
oxid
stress
cell
due
free
radic
reactiv
oxygen
speci
ro
gener
result
cellular
metabol
ie
infect
antioxid
agent
whose
action
limit
oxid
damag
benzotriazol
deriv
nphenylacetamid
acetylcarbam
acid
synthes
antioxid
activ
determin
follow
radic
activ
nitric
oxid
biolog
system
use
griess
reaction
presenc
nitric
oxid
synthes
compound
fig
abl
reduc
product
nitrit
ion
strong
oxid
agent
due
presenc
chemic
structur
carbonyl
amin
function
group
abl
interact
nitric
oxid
benzotriazol
substitut
nphenylacetamid
show
higher
antioxid
activ
analogu
substitut
acetylcarbam
acid
compound
show
remark
scaveng
activ
compar
ascorb
acid
narylkyl
deriv
abt
fig
synthes
isoformselect
suicid
inhibitor
cytochrom
p
nbenzyl
namethylbenzyl
abt
deriv
show
greatest
potenc
latter
effici
isoformselect
suicid
inhibitor
order
inactiv
isozym
monooxygenas
lung
orthologu
narylkyl
deriv
appear
inactiv
isoform
bind
apoprotein
final
antiemet
gastroprokinet
activ
evalu
seri
deriv
medium
perhydroazacycl
ring
amin
moieti
molecul
design
aim
obtain
peripher
dopamin
receptor
antagonist
particularli
deriv
fig
exhibit
strong
antiemet
activ
ed
mgkg
p
os
without
receptor
antagonist
activ
class
compound
extend
sar
analysi
pharmacolog
profil
evalu
perform
discoveri
novel
drug
mani
field
ie
antibacteri
stall
mani
year
urgent
need
new
pharmaceut
broader
spectrum
activ
act
novel
mechan
action
ie
overcom
increas
incid
microbi
resist
observ
current
use
drug
benzotriazol
regard
promis
class
bioactiv
heterocycl
compound
exhibit
rang
biolog
activ
therefor
nucleu
appear
interest
scaffold
drug
discoveri
develop
process
prove
paper
benzotrial
use
wide
develop
sar
analysi
differ
class
pharmacolog
agent
possibl
biolog
activ
benzotriazol
deriv
report
fig
isoster
modif
done
introduct
benzotriazol
moieti
sometim
success
lower
activ
nanomolar
concentr
one
hundr
molecul
present
virtual
hit
lead
compound
drug
develop
howev
despit
activ
exhaust
target
base
research
develop
mani
compound
antibacteri
antimycot
antimycobacteri
potassium
channel
activ
etc
molecul
made
way
market
clinic
probabl
due
lack
molecular
target
knowledg
compound
exert
biolog
action
also
due
lack
comprehens
compil
variou
research
report
activ
capabl
give
insight
sar
compound
present
review
cover
refer
expect
provid
lowheight
fli
bird
eye
view
benzotriazol
deriv
compound
drug
design
medicin
chemist
comprehens
target
orient
inform
develop
clinic
viabl
molecul
